Company: AEMD
Filing Date: 2025-06-26
Form Type: 10-K
Source: 0001683168-25-004780
Chunk: 866

Company: AETHLON MEDICAL INC
Filing Date: 2025-06-26
Form: 10-K
Item: Item 5
Chunk 866
---
 agreement with Dr. LaRosa, which governs the current terms of his employment with us. Dr. LaRosa’s
annual base salary was increased by the Compensation Committee to $430,000, effective May 1, 2021, when Dr. LaRosa assumed the additional
duties of interim Chief Scientific Officer, which he held until February 2023. In addition, we paid Dr. LaRosa a one-time signing bonus
of $100,000. Further, Dr. LaRosa was eligible to receive a grossed-up reimbursement of relocation expenses pursuant to the terms of his
employment agreement. In addition, the agreement provides that Dr. LaRosa is eligible for an annual cash performance bonus for each year
with a target amount of 40% of Dr. LaRosa’s then-current annual base salary, based upon our and Dr. LaRosa’s achievement of
objectives and milestones to be determined on an annual basis by the Board of Directors (or Compensation Committee thereof). Whether Dr.
LaRosa receives an annual bonus for any given year, and the amount of any such annual bonus, will be determined in the discretion of our
Board of Directors (or the Compensation Committee thereof). The agreement also provides that if Dr. LaRosa’s employment is terminated
without cause, or if he resigns for good reason (each as defined in the agreement), then Dr. LaRosa will be entitled under his agreement
to continue to receive his annual base salary and payment of premiums for continuation of healthcare benefits for a period of 12 months
following such termination.

 68 

Outstanding Equity Awards at 2025 Fiscal Year-End

The following table sets forth
certain information concerning equity awards granted to our named executive officers that remained outstanding as of March 31, 2025.

    OPTIONS AWARDS 
  
    Name 
    Grant Date  
    Number of Securities Underlying Unexercised Options Exercisable  (#)  
    Number of Securities Underlying Unexercised Options Unexercisable  (#)  
    Option Exercise Price ($)  
    Option Expiration  Date 
  
    James B. Frakes 
     4/3/2020  
     1,75620(1) 
     –  
     102.40  
     4/2/2030 
  
    Chief Executive Officer and 
     2/10/2022